^
Association details:
Biomarker:MET amplification
Cancer:Lung Cancer
Drug Class:c-MET inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

2133 / 7 - Next-generation sequencing-based MET focal amplification can predict treatment efficacy of MET inhibitors in lung cancer

Published date:
03/15/2023
Excerpt:
Our results suggest that MET focal amplification leads to oncogenic MET addiction and is associated with promising efficacy of MET inhibitors. MET focal amplification by NGS tests might be a feasible and powerful biomarker to identify LC patients who benefit from MET inhibitors.